NCT05968690View on ClinicalTrials.gov

Naltrexone and Propranolol Combined With Immunotherapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Advanced Melanoma
Interventions
DRUG

Propranolol

Propranolol will be administered to patients in all cohorts.

DRUG

Naltrexone

Naltrexone will be administered to patients in cohorts 2, 3, and 4.

Trial Locations (1)

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

Sarah Weiss

OTHER